Gadopiclenol vs Gadoxetate MRI for Liver Lesions

Enrolling by invitation

Conditions studied: Liver Lesion

In brief

The overall purpose of this study is to establish noninferiority of gadopiclenol MRI compared to gadoxetate MRI in terms of image quality and lesion detection/conspicuity in patients undergoing clinically indicated liver MRI in a prospective study. The research will be utilizing MRI; with enrollment goal of 75 subjects over the course of two years.

Key facts

Study ID

NCT06596616

Run by

Icahn School of Medicine at Mount Sinai

People needed

23

Starts

2024-07-01

Expected to finish

2027-01-01

Last updated by the study team

2026-04-22

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult patients of both genders and all ethnic groups with clinical indication of MRI for chronic liver disease and/or focal lesion and/or tumor treatment follow-up.

You may not qualify if…

• Acute renal insufficiency.
• Severe chronic renal insufficiency (GFR <30 mL/min/1.73 m2).
• Age <18y.
• Unable or unwilling to give informed consent.
• Contraindications for MRI (such as pacemakers, infusion pumps, pregnancy, allergy or previous adverse reactions to gadolinium contrast agents, severe claustrophobia).

Where it is running

• BMEII — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.